Pharmacovigilance in Nigeria: An Overview.
- Published in:
- Pharmaceutical Medicine, 2016, v. 30, n. 2, p. 87, doi. 10.1007/s40290-015-0133-3
- By:
- Publication type:
- Article
Works matching IS 11782595 AND DT 2016 AND VI 30 AND IP 2
Results: 8
1
2
Variation in Liver Biochemistries in Patients with Decompensated Cirrhosis: Implications for Assessing Drug-Induced Liver Injury in Clinical Trials.
- Published in:
- Pharmaceutical Medicine, 2016, v. 30, n. 2, p. 95, doi. 10.1007/s40290-015-0134-2
- By:
- Publication type:
- Article
3
Trends in the Location of Phase 3 Clinical Trials Between 2008 and 2012: A Retrospective Review Utilizing ClinicalTrials.gov.
- Published in:
- Pharmaceutical Medicine, 2016, v. 30, n. 2, p. 109, doi. 10.1007/s40290-015-0135-1
- By:
- Publication type:
- Article
4
A Method for Retrieval of Adverse Event Terms in Clinical Trial Databases Using Standardised MedDRA Queries.
- Published in:
- Pharmaceutical Medicine, 2016, v. 30, n. 2, p. 103, doi. 10.1007/s40290-016-0136-8
- By:
- Publication type:
- Article
5
Beyond the GAIN Act: Some Thoughts on Expediting Antibacterial Development to Address the Problem of Antimicrobial Resistance.
- Published in:
- Pharmaceutical Medicine, 2016, v. 30, n. 2, p. 71, doi. 10.1007/s40290-016-0137-7
- By:
- Publication type:
- Article
6
Major Pharmaceutical Conferences and Courses.
- Published in:
- Pharmaceutical Medicine, 2016, v. 30, n. 2, p. 129, doi. 10.1007/s40290-016-0139-5
- Publication type:
- Article
7
Forum.
- Published in:
- Pharmaceutical Medicine, 2016, v. 30, n. 2, p. 117, doi. 10.1007/s40290-016-0140-z
- Publication type:
- Article
8
Structured Qualitative Benefit-Risk Assessment to Inform Go/No-Go Decisions for Phase III Testing of Pharmaceutical Products.
- Published in:
- Pharmaceutical Medicine, 2016, v. 30, n. 2, p. 79, doi. 10.1007/s40290-015-0132-4
- By:
- Publication type:
- Article